The agreement allows CRISPR, a Swiss gene editing company, to gain access to the KSQ Therapeutics’ intellectual property (IP) for editing certain gene targets in its allogeneic oncology The post CRISPR, KSQ Therapeutics join forces to advance cell therapies in oncology appeared first on Pharmaceutical Business review.
“This partnership will significantly widen Trialbee’s service offerings to drive patient recruitment and retention,” said Lollo Eriksson, CEO of Trialbee. “This is a great opportunity to leverage both The post Trialbee and TriNetX partner to accelerate patient-centric clinical trials appeared first on Pharmaceutical Business review.
Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a The post Sun Pharma launches Drizalma Sprinkle in US appeared first on Pharmaceutical Business review.
The divestment is part of Takeda’s strategy to focus on core business areas and facilitate rapid deleveraging following its acquisition of Shire. Takeda growth and emerging markets business The post Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m appeared first on Pharmaceutical Business review.
According to the life sciences company, the technology used by the IonicX XRF Analyzer helps save time and money that is otherwise used on conventional analysis techniques. This The post Thermo Fisher launches IonicX XRF Analyzer to identity ionic salts appeared first on Pharmaceutical Business review.
Over time, patients taking levodopa may begin to experience periods when PD symptoms, including motor fluctuations, re-emerge between treatment doses. These are called “off” episodes. “We are pleased The post Kyowa Kirin launches NOURIANZ in US for treatment of Parkinson’s disease “Off” episodes appeared first on Pharmaceutical Business review.
Simultaneously, the company completed a Series C financing led by HBM Partners with participation from new and existing investors. AVID200 is rationally designed to selectively and potently inhibit The post Forbius completes enrollment into phase 1a solid tumour trial of AVID200 appeared first on Pharmaceutical Business review.
The approval has been granted for Xarelto to prevent venous thromboembolism (VTE) or blood clots in hospitalised acutely ill medical patients at risk for thromboembolic complications who are The post Janssen, Bayer get FDA nod for Xarelto to prevent VTE in acutely ill medical patients appeared first on Pharmaceutical Business review.
The PEMPHIX trial also showed that MabThera was superior to mycophenolate mofetil (MMF) in the late-stage trial held in adult patients. PEMPHIX has been taken up by Roche The post MabThera meets primary endpoint in PEMPHIX trial in pemphigus vulgaris appeared first on Pharmaceutical Business review.
Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to The post Pfizer presents positive phase 3 data for abrocitinib in moderate to severe atopic dermatitis appeared first on Pharmaceutical Business review.